Literature DB >> 25780324

Overcoming aspirin resistance with loading clopidogrel earlier in elective percutaneous coronary intervention.

Ozgur Ulas Ozcan1, Eralp Tutar1, Basar Candemir1, Elif Ezgi Ustun1, Cetin Erol1.   

Abstract

We aimed to analyze the clinical effect of clopidogrel loading time on adverse cardiovascular events among patients with aspirin resistance. Recurrent adverse events may still occur despite dual antiplatelet therapy after coronary stenting. Aspirin resistance is one of the possible reasons of this trouble. Optimal antiplatelet strategy for coronary stenting is unknown among patients with aspirin resistance. A total of 980 patients scheduled for elective coronary stenting were enrolled and allocated into two groups according to the loading time of clopidogrel more or less than 6 hours before coronary intervention (early- or late-loaded groups, respectively). Aspirin resistance was determined according to the urinary levels of 11-dehydrothromboxane B2. Overall 240 patients who were allocated to early- and late-loaded groups were identified as aspirin resistant according to the urinary levels of 11-dehydrothromboxane B2. After a follow-up period of 12 months major adverse cardiac events were observed among 16 patients (13.9%) in the early-loaded group and 30 patients (25.8%) in the late-loaded group (p = 0.02). Early loading of clopidogrel was an independent predictor of lower rate of cardiac events (hazard ratio = 0.46 [0.32-0.76, 95% confidence interval], p = 0.001). The rates of bleeding events and periprocedural myocardial infarction were similar in early- and late-loaded groups. The current study demonstrated that loading of clopidogrel earlier than 6 hours before elective coronary stenting among aspirin-resistant patients was associated with increased benefits for ischemic events with similar bleeding rates.

Entities:  

Keywords:  antiplatelet drugs; chronic stable angina; coronary artery disease; stents

Year:  2015        PMID: 25780324      PMCID: PMC4347830          DOI: 10.1055/s-0034-1395981

Source DB:  PubMed          Journal:  Int J Angiol        ISSN: 1061-1711


  21 in total

1.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.

Authors:  Glenn N Levine; Eric R Bates; James C Blankenship; Steven R Bailey; John A Bittl; Bojan Cercek; Charles E Chambers; Stephen G Ellis; Robert A Guyton; Steven M Hollenberg; Umesh N Khot; Richard A Lange; Laura Mauri; Roxana Mehran; Issam D Moussa; Debabrata Mukherjee; Brahmajee K Nallamothu; Henry H Ting
Journal:  J Am Coll Cardiol       Date:  2011-11-07       Impact factor: 24.094

2.  Comparison of adverse cardiovascular events and bleeding complications of loading dose of clopidogrel 300 mg versus 600 mg in stable patients undergoing elective percutaneous intervention (from the CADICE study).

Authors:  Andres Fernandez; Michael S Aboodi; Krzysztof Milewski; Juan A Delgado; Arturo Rodríguez; Juan F Granada
Journal:  Am J Cardiol       Date:  2011-01       Impact factor: 2.778

3.  Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.

Authors:  Tomas Jernberg; Christopher D Payne; Kenneth J Winters; Christelle Darstein; John T Brandt; Joseph A Jakubowski; Hideo Naganuma; Agneta Siegbahn; Lars Wallentin
Journal:  Eur Heart J       Date:  2006-04-18       Impact factor: 29.983

4.  2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.

Authors:  Gilles Montalescot; Udo Sechtem; Stephan Achenbach; Felicita Andreotti; Chris Arden; Andrzej Budaj; Raffaele Bugiardini; Filippo Crea; Thomas Cuisset; Carlo Di Mario; J Rafael Ferreira; Bernard J Gersh; Anselm K Gitt; Jean-Sebastien Hulot; Nikolaus Marx; Lionel H Opie; Matthias Pfisterer; Eva Prescott; Frank Ruschitzka; Manel Sabaté; Roxy Senior; David Paul Taggart; Ernst E van der Wall; Christiaan J M Vrints; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Juhani Knuuti; Marco Valgimigli; Héctor Bueno; Marc J Claeys; Norbert Donner-Banzhoff; Cetin Erol; Herbert Frank; Christian Funck-Brentano; Oliver Gaemperli; José R Gonzalez-Juanatey; Michalis Hamilos; David Hasdai; Steen Husted; Stefan K James; Kari Kervinen; Philippe Kolh; Steen Dalby Kristensen; Patrizio Lancellotti; Aldo Pietro Maggioni; Massimo F Piepoli; Axel R Pries; Francesco Romeo; Lars Rydén; Maarten L Simoons; Per Anton Sirnes; Ph Gabriel Steg; Adam Timmis; William Wijns; Stephan Windecker; Aylin Yildirir; Jose Luis Zamorano
Journal:  Eur Heart J       Date:  2013-08-30       Impact factor: 29.983

5.  Time dependence of clopidogrel loading effect: platelet activation versus platelet aggregation.

Authors:  Paul A Gurbel; Kevin P Bliden; Mark J Antonino; Tania Gesheff; Charles C Cummings; Benjamin V Dubois; William R Herzog; Udaya S Tantry
Journal:  Thromb Res       Date:  2011-08-20       Impact factor: 3.944

6.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.

Authors:  Steven R Steinhubl; Peter B Berger; J Tift Mann; Edward T A Fry; Augustin DeLago; Charles Wilmer; Eric J Topol
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

Review 7.  Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis.

Authors:  George Krasopoulos; Stephanie J Brister; W Scott Beattie; Michael R Buchanan
Journal:  BMJ       Date:  2008-01-17

Review 8.  Clopidogrel in coronary artery disease: update 2012.

Authors:  Kurt Huber
Journal:  Adv Cardiol       Date:  2012-08-09

Review 9.  Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.

Authors:  Anne Bellemain-Appaix; Stephen A O'Connor; Johanne Silvain; Michel Cucherat; Farzin Beygui; Olivier Barthélémy; Jean-Philippe Collet; Laurent Jacq; François Bernasconi; Gilles Montalescot
Journal:  JAMA       Date:  2012-12-19       Impact factor: 56.272

10.  A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.

Authors:  Patricia A Gum; Kandice Kottke-Marchant; Patricia A Welsh; Jennifer White; Eric J Topol
Journal:  J Am Coll Cardiol       Date:  2003-03-19       Impact factor: 24.094

View more
  2 in total

1.  Clinical Significance of Acute and Serial Platelet Function Testing in Acute Ischemic Stroke.

Authors:  Joon-Tae Kim; Kang-Ho Choi; Man-Seok Park; Ji Sung Lee; Jeffrey L Saver; Ki-Hyun Cho
Journal:  J Am Heart Assoc       Date:  2018-06-01       Impact factor: 5.501

2.  The Herb-Drug Interaction of Clopidogrel and Xuesaitong Dispersible Tablet by Modulation of the Pharmacodynamics and Liver Carboxylesterase 1A Metabolism.

Authors:  Shitang Ma; Guoliang Dai; Xiaolin Bi; Meirong Gong; Chenggui Miao; Hao Chen; Liangliang Gao; Weiman Zhao; Tianjun Liu; Ningru Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2018-10-18       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.